Market Intelligence, Clinical Progress, and High-Purity Reagents for Lymphoproliferative Disorders and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD52 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD52 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View CD52 Products |
| Gene Delivery | CD52 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for cell-based assays. |
View CD52 Products |
| Benchmark Ab | Anti-CD52 (Sequence of Alemtuzumab) Recombinant positive control for ADCC/CDC validation. |
View CD52 Products |
| Validator | CD52 siRNA Set For knockdown verification in target-positive cell lines. |
View CD52 Products |
| Related Target A | CD3 Synergistic pathway partner for bispecific T-cell engagers (BiTEs). |
View CD3 Products |
| Related Target B | CD20 Co-expressed B-cell marker; evaluated in combination therapies. |
View CD20 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Extremely small mature peptide size (12 AA) hindering recombinant expression | ECD-Fc fusion construct engineered to optimize presentation and stability. Sequence Verified. |
| Heavy O-glycosylation requirement for native epitope recognition | HEK293 mammalian expression system ensuring native-like post-translational modifications. |
| Lack of Reliable Screening Controls | Clinical Benchmark Antibody (Alemtuzumab biosimilar) included as a functional control. |
| Off-target and non-specific binding in cell-based assays | Sequence-verified siRNA included for target knockdown and specificity validation. |
Live CD52 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD52 therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific antibodies and CAR-T cell conditioning regimens. As first-generation therapies like Alemtuzumab reach mature clinical phases, the next wave of R&D is targeting next-generation depletion mechanisms with minimized cytokine release syndrome (CRS) and off-target toxicities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Sanofi, Genzyme | Multiple Sclerosis, CLL | ADCC/CDC Assay (Need Lentivirus for high-expression stable cell line construction) |
| Bispecific Antibody | Academic/Biotech Consortiums | T-cell Malignancies | Dual-target Binding Assay (Need high-purity CD52 and CD3 recombinant proteins) |
| Allogeneic CAR-T (Conditioning) | Allogene therapeutics | B-cell Malignancies | CD52 Knockout Verification (Need CD52 siRNA and flow-cytometry validated target lines) |